Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

We are excited to work with Abbott to empower healthcare providers and people living with diabetes to see data from their FreeStyle Libre sensors on Tidepool and Tidepool+,” said Brandon Arbiter ...

We are excited to work with Abbott to empower healthcare providers and people living with diabetes to see data from their FreeStyle Libre sensors on Tidepool and Tidepool+,” said Brandon Arbiter ...

Adding to this cascade of innovation in the U.S., we are on track to launch Omnipod 5 integrated with Abbott's FreeStyle Libre 2 Plus sensor by the end of the year. We are excited to provide ...

FreeStyle Libre 2 sensors will be phased out in the UK by the end of August 2025, meaning that people living with diabetes who use the sensors will need to transition to using FreeStyle Libre 2 Plus ...

Abbott's FreeStyle Libre 2 and 3 continuous glucose monitors no longer need to be removed for imaging tests. CGM readings during an MRI may be affected for up to an hour after the procedure. While ...

especially if they didn’t have a replacement sensor. The removal of the imaging contraindication from Abbott’s FreeStyle Libre 2 and 3 systems is a big win for patients, allowing them to keep their ...

Clinics and health systems using Tidepool+ can initiate the connection with patients using FreeStyle libre 2 and 3 systems in a clinic or remotely. Tidepool says its platform can seamlessly merge data ...